Gene-specific effects of antisense phosphorodiamidate morpholino oligomer-peptide conjugates on Escherichia coli and Salmonella enterica serovar typhimurium in pure culture and in tissue culture

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 8, 2006, Pages 2789-2796

  Tilley, Lucas D ^a   Hine, Orion S ^a   Kellogg, Jill A ^a   Hassinger, Jed N ^a   Weller, Dwight D ^a   Iversen, Patrick L ^a   Geller, Bruce L ^a,b  

^a AVI BIOPHARMA INC   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ARGINYL BIS(6 AMINOHEXANOIC ACID)ARGINYL BIS(6 AMINOHEXANOIC ACID)ARGINYL BIS(6 AMINOHEXANOIC ACID) BETA ALANINE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; ARGINYLPHENYLALANYLPHENYLALANYLARGINYLPHENYLALANYLPHENYLALANYLARGINYLPHENYL ALANYLPHENYLALANYL 6 AMINOHEXANOIC ACID BETA ALANINE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; ARGINYLTHREONYLARGINYLTHREONYLARGINYLPHENYLALANYLLEUCYLARGINYLARGINYLTHREON YL 6 AMINOHEXANOIC ACID BETA ALANINE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; LUCIFERASE; LYSYLPHENYLALANYLPHENYLALANYLLYSYLPHENYLALANYLPHENYLALANYLLYSYLPHENYLALANYL PHENYLALANYLLYSYL 6 AMINOHEXANOIC ACID BETA ALANINE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; MORPHOLINE DERIVATIVE; PHOSPHORIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ACPP GENE; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; CELL STRAIN CACO 2; CELL VIABILITY; COLONY FORMING UNIT; COVALENT BOND; DRUG EFFICACY; ENTEROPATHOGENIC ESCHERICHIA COLI; ENZYME INHIBITION; ENZYME SYNTHESIS; ESCHERICHIA COLI; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; SALMONELLA ENTERICA; START CODON; TISSUE CULTURE;

BACTERIAL PROTEINS; CACO-2 CELLS; CELL SURVIVAL; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; GENES, BACTERIAL; GENES, REPORTER; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; LUCIFERASES; MORPHOLINES; MUTATION; PEPTIDES; SALMONELLA TYPHIMURIUM; SEROTYPING;

EID: 33746920900     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01286-05     Document Type: Article

References (19)

1. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1998. Current protocols in molecular biology. John Wiley & Sons, Inc., New York, N.Y.
2. Cronan, J. E., Jr., and C. O. Rock. 1996. Biosynthesis of membrane lipids, p. 612-636. In F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed. ASM Press, Washington, D.C.
3. Deere, J., P. Iversen, and B. L. Geller. 2005. Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli. Antimicrob. Agents Chemother. 49:249-255.
4. Geller, B. L. 2005. Antibacterial antisense. Curr. Opin. Mol. Ther. 7:109-113.
5. Geller, B. L., J. D. Deere, D. A. Stein, D. Kroeker, H. M. Moulton, and P. L. Iversen. 2003. Inhibition of gene expression in Escherichia coli by antisense phosphorodiamidate morpholino oligomers. Antimicrob. Agents Chemother. 47:3233-3239.
6. Geller, B. L., J. Deere, L. Tilley, and P. L. Iversen. 2005. Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis. J. Antimicrob. Chemother. 55:983-988.
7. Good, L., S. K. Awasthi, R. Dryselius, O. Larsson, and P. E. Nielsen. 2001. Bacterial antisense effects of peptide-PNA conjugates. Nat. Biotechnol. 19:360-364.
8. Jackowski, S., and C. O. Rock. 1983. Ratio of active to inactive forms of acyl carrier protein in Escherichia coli. J. Biol. Chem. 258:16186-16191.
9. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5, 5th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
10. Nekhotiaeva, N., S. K. Awasthi, P. E. Nielsen, and L. Good. 2004. Inhibition of Staphylococcus aureus gene expression and growth using antisense peptide nucleic acids. Mol. Ther. 10:252-259.
11. Nelson, M. H., D. A. Stein, A. D. Kroeker, S. A. Hatlevig, P. L. Iversen, and H. M. Moulton. 2005. Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity. Bioconjug. Chem. 16:959-966.
12. Nielsen, P. E. 2004. PNA technology. Mol. Biotechnol. 26:233-248.
13. Nikaido, H. 1993. Transport across the bacterial outer membrane. J. Bioenerg. Biomembr. 25:581-589.
14. Polacco, M. L., and J. E. Cronan, Jr. 1981. A mutation of Escherichia coli conditionally defective in the synthesis of holo-[acyl carrier protein]. J. Biol. Chem. 256:5750-5754.
15. Summerton, J., and D. Weller. February 1993. Uncharged morpholino-based polymers having phosphorus containing chiral inter-subunit linkages. U.S. patent 5,185,444.
16. Summerton, J., and D. Weller. 1997. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7:187-195.
17. Tan, X.-X., J. K. Actor, and Y. Chen. 2005. Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection. Antimicrob. Agents Chemother. 49:3203-3207.
18. Varra, M., and M. Porro. 1996. Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrob. Agents Chemother. 40:1801-1805.
19. Zhang, Y., and J. E. Cronan, Jr. 1996. Polar allele duplication for transcriptional analysis of consecutive essential genes: application to a cluster of Escherichia coli fatty acid biosynthetic genes. J. Bacteriol. 178:3614-3620.